DVHGF (Devonian Health Group) ROIC %: -126.73% (As of Jan. 2026)


DVHGF Devonian Health Group Inc DVHGF
49 GF Score
Price $7.00
GF Value $3.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Devonian Health Group ROIC %?

Devonian Health Group DVHGF 49 ROIC % is -126.73% as of Jan. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Devonian Health Group's annualized return on invested capital (ROIC %) for the quarter that ended in Jan. 2026 was -126.73%.

As of today (2026-07-03), Devonian Health Group's WACC % is 6.31%. Devonian Health Group's ROIC % is -52.38% (calculated using TTM income statement data). Devonian Health Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Devonian Health Group  (OTCPK:DVHGF) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Devonian Health Group's WACC % is 6.31%. Devonian Health Group's ROIC % is -52.38% (calculated using TTM income statement data). Devonian Health Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Devonian Health Group ROIC % Related Terms


Devonian Health Group ROIC % Historical Data

* Premium members only.

The historical data trend for Devonian Health Group's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group ROIC % Chart

Devonian Health Group Annual Data
Trend Jun16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.56 -20.62 -28.28 -3.90 -7.16

Devonian Health Group Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.23 -22.50 -88.44 -126.73

DVHGF vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, Devonian Health Group's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Devonian Health Group ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Devonian Health Group's ROIC % distribution charts can be found below:

* The bar in red indicates where Devonian Health Group's ROIC % falls into.


DVHGF
49GF Score
Devonian Health Group Inc DVHGF
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devonian Health Group ROIC % Calculation

Devonian Health Group's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jul. 2025 is calculated as:

ROIC % (A: Jul. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jul. 2024 ) + Invested Capital (A: Jul. 2025 ))/ count )
=-0.563 * ( 1 - 0% )/( (10.495 + 5.224)/ 2 )
=-0.563/7.8595
=-7.16 %

where

Devonian Health Group's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jan. 2026 is calculated as:

ROIC % (Q: Jan. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2025 ) + Invested Capital (Q: Jan. 2026 ))/ count )
=-6.524 * ( 1 - 0% )/( (5.088 + 5.208)/ 2 )
=-6.524/5.148
=-126.73 %

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -126.73% mean?
Devonian Health Group (DVHGF) has a ROIC % of -126.73% as of Jan. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Devonian Health Group and its competitors.
Is Devonian Health Group's ROIC % too high?
Devonian Health Group's current ROIC % is -126.73%. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's ROIC % compare to VRTX and REGN?
Devonian Health Group's ROIC % of -126.73% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current ROIC % is -126.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current ROIC % is -126.73%. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current ROIC % is -126.73% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devonian Health Group (DVHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued. The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02. GuruFocus considers Devonian Health Group to be Significantly Overvalued.

Key valuation signals for DVHGF:

  • ROIC %: -126.73%
  • GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Devonian Health Group Business Description

Other Exchanges GSD:Canada
Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score

Get the complete analysis for DVHGF

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$3.02
GF Value